Woulgan® to be listed on UK Drug Tariff

Biotec Pharmacon’s wholly owned subsidiary Biotec BetaGlucans has received feedback from the NHS that Woulgan® will be listed on the UK Drug Tariff from January 2018.

-This is a key milestone for us because it gives Woulgan access to a major European market. It is also a strong signal to other markets because an objective analysis has concluded that Woulgan is not only clinically effective, but also cost effective in the treatment of challenging wounds. We will now focus our efforts on a successful launch in January 2018, says CEO Christian Jørgensen.

The strategy for Woulgan® is to establish a portfolio of advanced wound care products based on the Company’s proprietary beta-glucan technology.